首页> 外文期刊>Cytometry, Part B. Clinical cytometry: the journal of the International Society for Analytical Cytology >Inability of a monoclonal anti-light chain antibody to detect clonal plasma cells in a patient with multiple myeloma by multicolor flow cytometry.
【24h】

Inability of a monoclonal anti-light chain antibody to detect clonal plasma cells in a patient with multiple myeloma by multicolor flow cytometry.

机译:单克隆抗轻链抗体无法通过多色流式细胞术检测多发性骨髓瘤患者的克隆浆细胞。

获取原文
获取原文并翻译 | 示例
           

摘要

Multicolor flow cytometry (MFC) is increasingly important for the diagnosis and minimal residual disease (MRD) assessment of patients with plasma cells (PC) dyscrasias, like multiple myeloma. Recently published information shows that immunophenotype of myeloma PC can change over time and normal PC are heterogeneous in the expression of CD19 and CD56. This implies that for a sensitive, reliable detection of MRD clonality assessment by the detection of cytoplasmic kappa and lambda light chains is advisable. Eight-color MFC was used to detect normal and myeloma PC by the expression of CD38 and CD138. Analysis of additional surface antigens like CD45, CD19, CD56, CD27, and the intracellular immunoglobulin light chain distribution were used to differentiate polyclonal from clonal PC. Absence of cytoplasmic light chains expression in a PC subpopulation with an abnormal phenotype suggested the presence of non-secretory plasma cells in the bone marrow (BM) of this patient. This observation however, was contradicted by the presence of free lambda light chains in the patient's serum. After repeating the analysis with polyclonal antibodies against intracellular immunoglobulin light chains instead of monoclonal antibodies, the abnormal PC subpopulation appeared to express lambda light chains. These data illustrate that if clonality assessment of PC is included in disease monitoring, the use of polyclonal over monoclonal antibodies is preferred for the detection of intracellular immunoglobulin light chains.
机译:多色流式细胞术(MFC)对于浆细胞(PC)异常型(如多发性骨髓瘤)患者的诊断和最小残留疾病(MRD)评估越来越重要。最近发布的信息表明,骨髓瘤PC的免疫表型可以随时间变化,而正常PC在CD19和CD56的表达中是异质的。这暗示了对于通过检测细胞质κ和λ轻链进行MRD克隆性评估的灵敏,可靠的检测是可取的。使用八色MFC通过CD38和CD138的表达检测正常和骨髓瘤PC。分析其他表面抗原,例如CD45,CD19,CD56,CD27和细胞内免疫球蛋白轻链分布,以区分多克隆与克隆PC。在具有异常表型的PC亚群中缺乏胞质轻链表达,表明该患者的骨髓(BM)中存在非分泌性浆细胞。但是,该观察结果与患者血清中存在游离λ轻链相矛盾。用针对细胞内免疫球蛋白轻链的多克隆抗体而不是单克隆抗体重复分析后,异常的PC亚群似乎表达了λ轻链。这些数据表明,如果在疾病监测中包括PC的克隆性评估,则检测细胞内免疫球蛋白轻链优先使用多克隆抗体,而不是单克隆抗体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号